Determining Eligibility: Who Can Take Mounjaro for Diabetes and Weight Management

Last reviewed: July 10, 2026

Last updated: July 10, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Tirzepatide is a dual-action GLP-1 and GIP receptor agonist that has demonstrated weight loss of up to 22% in clinical trials when combined with lifestyle changes. Understanding your eligibility for this medication is the first step toward personalized metabolic support. PlexusDx offers compounded tirzepatide injections from licensed 503A pharmacies to qualified candidates throughout the United States.

Basic Medical Criteria for Tirzepatide Therapy

Most adults with a BMI of 27 or higher, or those with a BMI of 25+ who have weight-related health conditions, may be candidates for tirzepatide treatment. Weight-related conditions include type 2 diabetes, high blood pressure, heart disease, or sleep apnea. Your medical history, current medications, and existing health conditions determine whether tirzepatide is appropriate for your situation.

A comprehensive health assessment with PlexusDx identifies any contraindications before you start therapy. Patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 are not suitable candidates. Pregnancy and breastfeeding also preclude tirzepatide use due to insufficient safety data in these populations.

Age, Kidney Function, and Heart Health Considerations

Adults age 18 and older can take tirzepatide if kidney and heart function meet safety thresholds. Your doctor or PlexusDx provider may order baseline blood work to assess kidney function, liver enzymes, and glucose levels. Severe kidney disease or recent heart surgery requires careful evaluation before starting any GLP-1 or GIP therapy.

Patients with a history of pancreatitis should discuss this with their PlexusDx provider, as tirzepatide may carry a small risk of inflammation. Those taking certain diabetes medications, particularly sulfonylureas, may need dose adjustments when starting tirzepatide to prevent low blood sugar. PlexusDx providers review all current medications to avoid harmful drug interactions.

How PlexusDx Assesses Your Tirzepatide Candidacy

PlexusDx uses a streamlined telehealth intake process to evaluate your medical history, current weight, BMI, and metabolic health. You complete a health questionnaire detailing past surgeries, medications, allergies, and chronic conditions. A licensed provider reviews your information and may recommend lab work or additional screening before approval.

The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month) analyzes GLP1R (rs6923761), and GIPR (rs1800437) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Getting Started: No Insurance Required, HSA/FSA Eligible

PlexusDx tirzepatide injections start at $289/mo (or $249/mo on the 6-month plan) across all three commitment tiers—your dose may need to go up, but your price won't. No membership fees, insurance requirements, or pre-authorization delays stand between you and treatment. All medications come from licensed 503A compounding pharmacies, ensuring pharmaceutical-grade quality and safety.

Payments are HSA and FSA eligible, reducing your out-of-pocket cost if you use a health savings account. PlexusDx ships compounded tirzepatide directly to your home in all 50 states within days of provider approval. If you prefer oral tirzepatide, that option starts at $349/mo (or $279/mo on the 6-month plan), and a dual-compound GLP-Squared injection combining semaglutide and tirzepatide begins at $289/month for those seeking enhanced peptide synergy.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $289/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What BMI do I need to qualify for tirzepatide with PlexusDx?

A BMI of 27 or higher generally qualifies you for tirzepatide; those with a BMI of 25+ who have weight-related health conditions like type 2 diabetes or high blood pressure may also be eligible. PlexusDx providers assess your individual case during the telehealth intake to confirm candidacy and determine the best starting approach for your metabolic needs.

Can I take tirzepatide if I have type 2 diabetes?

Yes, tirzepatide is approved for type 2 diabetes management and often produces significant improvements in blood sugar control alongside weight loss. However, if you take sulfonylurea drugs, your PlexusDx provider may adjust dosing to prevent hypoglycemia, and regular blood sugar monitoring is essential during treatment initiation.

How much does tirzepatide injection cost through PlexusDx?

Compounded tirzepatide injections start at $289/mo (or $249/mo on the 6-month plan) with no flat per-compound pricing increases. Your dose may need to go up as you progress through therapy, but your monthly price remains consistent. PlexusDx serves all 50 states without insurance requirements, and treatment is HSA/FSA eligible to lower your actual cost.

What disqualifies me from taking tirzepatide?

A personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN2) are absolute contraindications. Pregnancy, breastfeeding, severe kidney disease, and uncontrolled pancreatitis also generally disqualify candidates. PlexusDx providers conduct a thorough medical review to identify any safety concerns before treatment approval.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, and GIPR) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Mounjaro For Losing Weight
• Mounjaro For Weight Loss 2
• Weight Loss Mounjaro
• Mounjaro Weight Loss By Week

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.